Research/art/teacher profile of a person
Name and surname:
doc. MUDr. Juraj Sokol, PhD., MBA
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Sokol
I.2 - Name
Juraj
I.3 - Degrees
assoc. prof., MD, PhD.
I.4 - Year of birth
1985
I.5 - Name of the workplace
Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Hematology and Transfusion Medicine
I.6 - Address of the workplace
Kollarova 2, 036 59 Martin
I.7 - Position
assoc. prof.
I.8 - E-mail address
juraj.sokol@uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/17989?do=filterForm-submit&name=Juraj&surname=Sokol&sort=surname&employment_state=yes&filter=Vyhľadať
I.10 - Name of the study field in which a person works at the university
General Medicine
I.11 - ORCID iD
0000-0003-2786-0505

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin
II.b - Year
2010
II.c - Study field and programme
General Medicine
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin
II.b - Year
2014
II.c - Study field and programme
General Medicine, Internal Diseases
II.4 - Associate professor
II.a - Name of the university or institution
Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin
II.b - Year
2019
II.c - Study field and programme
General Medicine, Internal Diseases
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
assistent Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin 1.9.2014 - 31.1.2020
Associate Professor omenius University in Bratislava, Jessenius Faculty of Medicine in Martin 1.2.2020 -

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Hematology and Transfusion Medicine General Medicine I.+II. General Medicine
Hematology and Transfusion Medicine General Medicine I.+II. General Medicine
Hemostasis - Vascular Medicine General Medicine I.+II. General Medicine
Hemostasis - Vascular Medicine General Medicine I.+II. General Medicine
Internal diseases 1 Internal diseases III. General Medicine
Internal diseases 1 Internal diseases III. General Medicine
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
5
V.4.c - Dissertation (third degree)
3
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
23
V.4.c - Dissertation (third degree)
0
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Propaedeutics of internal diseases General Medicine I.+II. General Medicine
Propaedeutics of internal diseases General Medicine I.+II. General Medicine
Internal diseases 5 General Medicine I.+II. General Medicine
Internal diseases 5 General Medicine I.+II. General Medicine
Internal diseases - gerontology and nursing 2 Nursing I. Nursing

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
506
VI.1.b - Over the last six years
229
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
54
VI.1.b - Over the last six years
40
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
467
VI.1.b - Over the last six years
301
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
367
VI.1.b - Over the last six years
289
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
8
VI.1.b - Over the last six years
6
VI.2 - The most significant research/artistic/other outputs
1

Sokol, Juraj (aut) [KAUT] [UKOLJ308] (20%) - Nehaj, František (aut) [UKOLJ] (20%) - Mokáň, Michal (aut) [UKOLJ220] (20%) - Lisá, Lenka (aut) [UKOLJ308] (20%) - Staško, Ján (aut) [UKOLJ308] (20%): COVID19 infection in a patient with paroxysmalnocturnal hemoglobinuria [elektronický dokument] : a case report

Lit.: 19 zázn.

In: Medicine [elektronický dokument]. - Roč.

100, č. 20 (2021), s. [1-4], art. no. 25456 [print]. - ISSN (print) 0025-7974

článok

180 Lekárske, farmaceutické a nelekárske

zdravotnícke vedy 

URL:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137037/

Registrované

v: 

CCC Current Content Connect 

MEDLINE

SCO SCOPUS 

WOS CC Web of Science Core Collection 

SCIE Science Citation Index Expanded 

Indikátor

časopisu:

SJR (SCOPUS) 2021=0.470

SNIP (SCOPUS) 2021=1.009

CiteScore (SCOPUS) 2021=2.7

IF (JCR) 2021=1.817

AIS (JCR) 2021=0.482

Ohlasy: 5/4

2

Sokol, Juraj [KAUT] [UKOLJ308] (65%) - Škereňová, Mária [UKOLJ110] (20%) - Jedináková, Zuzana (5%) - Šimurda, Tomáš [UKOLJ308] (2%) - Škorňová, Ingrid [UKOLJ] (2%) - Staško, Ján [UKOLJ308] (2%) - Kubisz, Peter [UKOLJ] (4%): Progress in the Understanding of Sticky Platelet Syndrome

In: Seminars in Thrombosis and Hemostasis. - Volume. 43, No. 1 (2017), p. 8-13. - ISSN 0094-6176

scopus and wos

IF (JCR) 2017=3.345

Citations: 26/20

3

Sokol, Juraj [UKOLJ308] (80%) - Timp, J. F. (2%) - Le cessie, S. (1%) - Van Hylckama-Vlieg, A. (1%) - Rosendaal, F. R. (1%) - Kubisz, Peter [UKOLJ308] (3%) - Cannegieter, S. C. (2%) - Lijfering, W. M. [KAUT] (10%): Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study

Lit.: 25 zázn.

In: Journal of Thrombosis and Haemostasis. - Volume. 16, No. 4 (2018), p. 680-688. - ISSN (print) 1538-7933

scopus and wos

SJR (SCOPUS) 2018=2.026

SNIP (SCOPUS) 2018=1.526

CiteScore (SCOPUS) 2018=8.3

IF (JCR) 2018=4.662

Kvartil Q:

wos-jcr -- Q1 [Peripheral vascular disease] -- 2018

wos-jcr -- Q2 [Hematology] -- 2018

scimago-sjr -- Q1 [Hematology] -- 2018

scimago-sjr -- Q1 [Medicine (miscellaneous)] -- 2018

Citations: 26/21

4

Sokol, Juraj [KAUT] [UKOLJ308] (65%) - Škereňová, Mária [UKOLJ110A] (20%) - Ivanková, Jela (10%) - Šimurda, Tomáš [UKOLJ308] (3%) - Staško, Ján [UKOLJ308] (2%): Association of Genetic Variability in Selected Genes in Patients With Deep VeinThrombosis and Platelet Hyperaggregability [elektronický dokument]

In: Clinical and Applied Thrombosis/Hemostasis [elektronický dokument]. - Volume 24, No. 7 (2018), p. 1027-1032 [print]. - ISSN (print) 1076-0296

scopus and wos

SJR (SCOPUS) 2018=0.452

SNIP (SCOPUS) 2018=0.728

CiteScore (SCOPUS) 2018=2.5

IF (JCR) 2018=1.846

Kvartil Q:

wos-jcr -- Q4 [Hematology] -- 2018

wos-jcr -- Q4 [Peripheral vascular disease] -- 2018

scimago-sjr -- Q2 [Medicine (miscellaneous)] -- 2018

scimago-sjr -- Q3 [Hematology] -- 2018

Citations: 19/16

5

Sokol, Juraj [KAUT] [UKOLJ308] (60%) - Škereňová, Mária [UKOLJ110A] (25%) - Biringer, Kamil [UKOLJ150] (5%) - Šimurda, Tomáš [UKOLJ308] (5%) - Kubisz, Peter [UKOLJ308] (3%) - Staško, Ján [UKOLJ308] (2%): Glycoprotein VI Gene Variants Affect Pregnancy Loss in Patients With Platelet Hyperaggregability [elektronický dokument]

In: Clinical and Applied Thrombosis/Hemostasis [elektronický dokument]. - Volume 24, No. 9 (2018), p. 202S-208S [print]. - ISSN (print) 1076-0296

wos and scopus

SJR (SCOPUS) 2018=0.452

SNIP (SCOPUS) 2018=0.728

CiteScore (SCOPUS) 2018=2.5

IF (JCR) 2018=1.846

Kvartil Q:

wos-jcr -- Q4 [Hematology] -- 2018

wos-jcr -- Q4 [Peripheral vascular disease] -- 2018

scimago-sjr -- Q2 [Medicine (miscellaneous)] -- 2018

scimago-sjr -- Q3 [Hematology] -- 2018

Citations: 13/11

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Sokol, Juraj [KAUT] [UKOLJ308] (65%) - Škereňová, Mária [UKOLJ110] (20%) - Jedináková, Zuzana (5%) - Šimurda, Tomáš [UKOLJ308] (2%) - Škorňová, Ingrid [UKOLJ] (2%) - Staško, Ján [UKOLJ308] (2%) - Kubisz, Peter [UKOLJ] (4%): Progress in the Understanding of Sticky Platelet Syndrome

In: Seminars in Thrombosis and Hemostasis. - Volume. 43, No. 1 (2017), p. 8-13. - ISSN 0094-6176

scopus and wos

IF (JCR) 2017=3.345

Citations: 26/20

2

Sokol, Juraj [UKOLJ308] (80%) - Timp, J. F. (2%) - Le cessie, S. (1%) - Van Hylckama-Vlieg, A. (1%) - Rosendaal, F. R. (1%) - Kubisz, Peter [UKOLJ308] (3%) - Cannegieter, S. C. (2%) - Lijfering, W. M. [KAUT] (10%): Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study

Lit.: 25 zázn.

In: Journal of Thrombosis and Haemostasis. - Volume. 16, No. 4 (2018), p. 680-688. - ISSN (print) 1538-7933

scopus and wos

SJR (SCOPUS) 2018=2.026

SNIP (SCOPUS) 2018=1.526

CiteScore (SCOPUS) 2018=8.3

IF (JCR) 2018=4.662

Kvartil Q:

wos-jcr -- Q1 [Peripheral vascular disease] -- 2018

wos-jcr -- Q2 [Hematology] -- 2018

scimago-sjr -- Q1 [Hematology] -- 2018

scimago-sjr -- Q1 [Medicine (miscellaneous)] -- 2018

Citations: 26/21

3

Sokol, Juraj [KAUT] [UKOLJ308] (65%) - Škereňová, Mária [UKOLJ110A] (20%) - Ivanková, Jela (10%) - Šimurda, Tomáš [UKOLJ308] (3%) - Staško, Ján [UKOLJ308] (2%): Association of Genetic Variability in Selected Genes in Patients With Deep VeinThrombosis and Platelet Hyperaggregability [elektronický dokument]

In: Clinical and Applied Thrombosis/Hemostasis [elektronický dokument]. - Volume 24, No. 7 (2018), p. 1027-1032 [print]. - ISSN (print) 1076-0296

scopus and wos

SJR (SCOPUS) 2018=0.452

SNIP (SCOPUS) 2018=0.728

CiteScore (SCOPUS) 2018=2.5

IF (JCR) 2018=1.846

Kvartil Q:

wos-jcr -- Q4 [Hematology] -- 2018

wos-jcr -- Q4 [Peripheral vascular disease] -- 2018

scimago-sjr -- Q2 [Medicine (miscellaneous)] -- 2018

scimago-sjr -- Q3 [Hematology] -- 2018

Citations: 19/16

4

Sokol, Juraj [KAUT] [UKOLJ308] (60%) - Škereňová, Mária [UKOLJ110A] (25%) - Biringer, Kamil [UKOLJ150] (5%) - Šimurda, Tomáš [UKOLJ308] (5%) - Kubisz, Peter [UKOLJ308] (3%) - Staško, Ján [UKOLJ308] (2%): Glycoprotein VI Gene Variants Affect Pregnancy Loss in Patients With Platelet Hyperaggregability [elektronický dokument]

In: Clinical and Applied Thrombosis/Hemostasis [elektronický dokument]. - Volume 24, No. 9 (2018), p. 202S-208S [print]. - ISSN (print) 1076-0296

wos and scopus

SJR (SCOPUS) 2018=0.452

SNIP (SCOPUS) 2018=0.728

CiteScore (SCOPUS) 2018=2.5

IF (JCR) 2018=1.846

Kvartil Q:

wos-jcr -- Q4 [Hematology] -- 2018

wos-jcr -- Q4 [Peripheral vascular disease] -- 2018

scimago-sjr -- Q2 [Medicine (miscellaneous)] -- 2018

scimago-sjr -- Q3 [Hematology] -- 2018

Citations: 13/11

5

Sokol, Juraj [UKOLJ308] (40%) - Nehaj, František [KAUT] [UKOLJ] (40%) - Ivanková, Jela (10%) - Mokáň, Michal [UKOLJ220] (8%) - Mokáň, Marián [UKOLJ220] (2%): First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation[elektronický dokument]

Lit.: 7 zázn.

In: Journal of Thrombosis and Thrombolysis [elektronický dokument]. - Volume 46, No. 3 (2018), p. 393-398 [print]. - ISSN (print) 0929-5305

scopus and wos

SJR (SCOPUS) 2018=0.995

SNIP (SCOPUS) 2018=1.115

CiteScore (SCOPUS) 2018=4.8

IF (JCR) 2018=2.941

Kvartil Q:

wos-jcr -- Q3 [Peripheral vascular disease] -- 2018

wos-jcr -- Q3 [Cardiac & cardiovascular systems] -- 2018

wos-jcr -- Q3 [Hematology] -- 2018

scimago-sjr -- Q1 [Cardiology and cardiovascular medicine] -- 2018

scimago-sjr -- Q2 [Hematology] -- 2018

Citations: 9/8

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Croles FN, Mulder R, Mulder AB, Lukens MV, Meijer K. β-Antithrombin, subtype of antithrombin deficiency and the risk of venous thromboembolism in hereditary antithrombin deficiency: A family cohort study. Thromb Res. 2018 Aug;168:47-52. doi: 10.1016/j.thromres.2018.06.004. IF(2018)=3.266

2

de la Morena-Barrio ME, Wypasek E, Owczarek D, Miñano A, Vicente V, Corral J, Undas A. MPI-CDG with transient hypoglycosylation and antithrombin deficiency. Haematologica. 2019 Feb;104(2):e79-e82. doi: 10.3324/haematol.2018.211326.  IF(2019)=7.116

3

Croles FN, Lukens MV, Mulder R, de Maat MPM, Mulder AB, Meijer K. Monitoring of heparins in antithrombin-deficient patients. Thromb Res. 2019 Mar;175:8-12. doi: 10.1016/j.thromres.2019.01.007. IF(2019)=2.869

4

Li-Gao R, Mook-Kanamori DO, Cannegieter SC, Willems van Dijk K, Rosendaal FR, van Hylckama Vlieg A. The association of genetic variants in the cholesteryl ester transfer protein gene with hemostatic factors and a first venous thrombosis. J Thromb Haemost. 2019 Sep;17(9):1535-1543. doi: 10.1111/jth.14528. IF(2019)=4.365

5

Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R; Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J Thromb Haemost. 2020 Jan;18(1):17-22. doi: 10.1111/jth.14648. IF (2020)=5.824

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

Grant VEGA 1/0187/17 - "Genetic Background and Hemostatic Changes in the Patients with von Willebrand Disease", principal investigator

Characteristic: Von Willebrand disease (vWD) is the most common inherited bleeding disorder. It was proved that conventional diagnostic methods are not sensitive sufficiently for the assessment of the diagnosis. Therefore, vWF multimer analysis and genetic testing can classify the patients with vWD more properly. These all are the reasons for the centralization of the individuals with vWD in one reference dagnostic centre with the availability to classify the subject with vWD rapidly in the acute clinical situations, for the pharmacovigilance, national planning of the care for such patients and budget allocation. Currently, such comprehensive centre with universal diagnostic algorithm is missing in Slovak Republic. The prominent aim of the proposed project was therefore the correlation of the laboratory results and genetic analysis with clinical course of the disease, their use for the indication, monitoring and subsequent individual management of the substitution treatment of the individuals with vWD.

2

Grant APVV-17-0054 - "New Oral Anticoagulants in the Prevention of Major Cardiovascular Diseases, their Effect on Thrombocytes, Drug Interactions, Safety and Possibilities of the Therapy in Oncology Patients", co-investigator

Characteristic: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Currently, four oral anticoagulants (NOAC), known as dabigatran, rivaroxaban, apixaban and edoxaban are currently used for anticoagulation therapy. The treatment with NOAC has been approved as alternatives to warfarin in patients with AF. The data of evidence-based and post-marketing literature on the benefit/risk ratio of NOACs are limited, conflicting, potentially biased and finally inconclusive in population of patients with AF. The aim of the study is to assess and compare the real benefits and harms of all three NOACs in routine practice. The main objective is to estimate and compare a composite event including major bleeding, thromboembolism (TE) and death from any cause.The secondary objectives are: to identify factors associated with the occurrence of major bleeding events and TE events in patients exposed to oral anticoagulant, to describe others adverse drug reactions, to compare the reliability of the monitoring of the NOACs by thrombelastometry, to assess the effect of NOACs on platelet aggregation and function, to assess the selected polymorphisms of drug-metabolising enzyme and to evaluate the drug interaction. The main outcome of the project is to improve the quality of health care and perioperative outcomes. The study could lead to a better understanding of the metabolic processes, platelet aggregation and genetic background of NOACs. The development of new monitoring methods will allow rapid assessment of coagulation activity in an emergency situation. This study has a major premise of interdisciplinary character, while the prevalence of patients taking NOAC refers to the high numbers in all fields of medicine.

3

Grant APVV-16-0020 - "Specific laboratory monitoring of platelet reactivity in patients with acute myocardial infarction treated with new P2Y12 receptor antagonists", co-investigator

Characteristic: P2Y12 ADP receptor blocker (ADPRB) treatment forms currently the basis of pharmacotherapy in acute coronary syndrome (ACS) patients, and in patients after percutaneous coronary interventions (PCI). However, nowadays, there are lots of data demonstrating an association between insufficient ADPRB on-treatment response and the risk of ischemic events, including stent trombosis, which is an uncommon but life-threatening complication in patients after PCI. High on-treatment platelet reactivity may be detected with several laboratory tests. Light transsmition aggregometry with ADP induction is so far con- sidered to be a „golden standard“, and VASP (vasodilator stimulated phosphoprotein) phosphorylation assessement using flow cytometry is probably the most specific test for the assessment of insuficient platelet response. If high on-treatment platelet reactivity is detected, this phenomenon migh be overcome with increased ADPRB dosing, ADPRB switch (e. g. switch of clopidogrel to prasugrel), or with the addition of other antiplatelet agent. The administration of cangrelor – a new par- enteral ADPRB – might be another perspective way how to overcome the phenomenon of insuficient ADPRB on-treatment response. 

4

Grant VEGA 1/0479/21 - "Molecular-genetic aspects of platelet hyperagregability in patients with venous thromboembolism", Deputy Principal Investigator

Characteristic: Platelet hyperaggregability after low concentrations of platelet agonists adenosine diphoshate (ADP) and/or epinephrine (EPI), referred to as sticky platelet syndrome (SPS), was first described by Holiday at the Ninth Conference on Stroke and Cerebral Circulation in Arizona in 1983. Clinical symptoms of SPS include unexplained arterial and venous thrombotic events, commonly occurring in stressful situations, and frequently recurrent under oral anticoagulant therapy. Furthermore, there is evidence for a causal relation between SPS and abortion. SPS is classified as type I (hyperaggregation after both ADP and EPI), type II (hyperaggregation after EPI alone) and type III (hyperaggregation after ADP alone). SPS type II seems to be the most common form. SPS is probably a hereditary, autosomal dominant thrombophilia, although the exact genetic cause has not as yet been identified. It has been suggested that defects of the platelet membrane glycoproteins or intracellular signal pathways involved in platelet activation and aggregation are responsible for the disorder.

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
member Slovak Society on Haemostasis and Thrombosis from 2010
member Slovak Society of Hematology and Transfusion Medicine from 2010
the president HematologySK, civic association from 2015

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Leiden University Medical Center, Leiden, The Nederlands Albinusdreef 2, 2333 ZA Leiden, The Nederlands May 1 to July 31, 2015 European Social Fund
University of North Carolina, Chapel Hill, North Carolina, USA 101 Manning Dr, Chapel Hill, NC 27514, USA August 27, 2017 - February 28, 2018 Fulbright Program

IX. - Other relevant facts

Date of last update
2025-02-28